—
C+
C+ The full Closelooknet — membership. Open the C+ overview

GlaxoSmithKline PLC ADR (GSK) — chart, structure and Closelooknet read

Pick a ticker to load its detail page.

Signals for this name

Every Closelooknet reading that exists for GSK, from the same nightly bakes the boards use. Research diary readings, not advice.

Weather around the name 3 macro readings: Money Temperature, Factor regime, Sovereign pressure

The weather around this name

Macro readings that apply by membership — the regime, the factor tape, the sector cell, the funding backdrop.

  • Money Temperature Composite 61/100 · S&P 500 fund at 75, bullish alignedEight instruments scored on position, momentum, volume, volatility and fragility — the regime every name trades inside. Temperature lab → 2026-10-06
  • Factor regime Momentum leading — risk appetite buildingMomentum against low volatility (SPMO / SPLV): above its 50-day trend, 98th percentile of the window, +5.7% over 20 sessions. Factor regime → 2026-10-06
  • Sovereign pressure Index 0.74 · up 0.17 over 21 sessionsG7 long-end yields, 10s30s and the slope — the funding weather for every balance sheet on this site. Sovereign pressure → 2026-10-06
How it trades on rate days beta 0.72 to TLT · on the worst bond days it fell more than the market

How it trades on rate days

How GSK has moved when long-dated Treasury yields rise — measured against TLT, the 20+ year Treasury fund.

  • Beta to long bonds, 1 year 0.72 — moves strongly with bonds for every 1% move in TLT (20+ year Treasuries), GlaxoSmithKline PLC ADR moved 0.72% on average · correlation 0.26 · higher than 72% of US names
  • Beta, last 3 months 0.98 more rate-sensitive lately than over the year
  • On the 10 worst bond days −1.04% on average against −0.74% for the S&P 500 the 10 sessions of the past year in which TLT fell most, i.e. long yields rose most
  • Latest of those days −0.12% TLT −1.29% that day 2026-09-24

Daily total returns from the adjusted price series; a TLT down day is a day long yields rose. Beta = the average move of the name for a 1% move in TLT. Past sensitivity, not a forecast. An investment diary, not a recommendation.

Who it is priced against Drug Manufacturers - General · US · 8 names with week and year-to-date

Peer group

Drug Manufacturers - General · US

This name carries no Closelooknet score, so its cohort ranks on trend state — distance to the 50- and 200-day averages — never on a score it does not have.

Compared against GSK on the nightly bakes; the Peers tab ranks the cohort on the Closelooknet scores where it exists.

Company snapshot — GlaxoSmithKline PLC ADR

GSK in five paragraphs: what it makes and sells, where it sits in the Closelooknet stack, who it is priced against, why we track it, what we watch. Research diary, not advice.

What it does
GSK researches, develops and manufactures vaccines and medicines through two segments, Commercial Operations and Total R&D. It sells specialty medicines for oncology, respiratory conditions and immune disease, vaccines against shingles, meningitis, RSV and other infections, and general medicines for asthma and COPD. It also runs partnerships, including work with CureVac on mRNA vaccines and AN2 Therapeutics on tuberculosis treatments. It is headquartered in London and was renamed from GlaxoSmithKline to GSK.
Where it sits in the stack
GSK holds no seat in our index and sits outside the layers the diary tracks for the AI build-out. It belongs to the Healthcare sector of Closelooknet's universe, classified under drug manufacturers.
Who it is priced against
Closelooknet groups it with scored healthcare names sharing its sector and country: argenx, Medpace, BeiGene, Globus Medical, Regeneron, Veeva Systems, Vertex Pharmaceuticals and Corcept Therapeutics. The market also names Pfizer as a comparable large drugmaker.
Why Closelooknet tracks it
GSK carries a Closelooknet score, with quality its strongest module and momentum its weakest. It has no index seat and no recorded quotes in the diary so far.
What the diary watches
Whether the recent broker downgrade to Sector Perform from Outperform coincides with further softening in the momentum reading already flagged as weak.

GlaxoSmithKline PLC ADR (GSK) trades on US exchanges.

Written from the company’s public profile and Closelooknet’s own readings, 2026-09-17. Descriptive, refreshed with the registry; corrections welcome via the imprint. closelook.net is an investment research diary — market structure, index membership and scores are our own readings, not investment advice. Related: index compare · sector dispersion · scanner.

The Street on this name 1 analyst action on the wire · latest: initiation by RBC Capital, 2026-09-08

The Street on this name

Analyst actions and the latest print for GSK from the Closelooknet wires — third-party opinions on the record, not our readings.

  • Initiation RBC Capital — at Sector Perform Initiated to Sector Perform from Outperform 2026-09-08

1 action on the analyst wire since 2026-08-13: 1 initiation. Analyst wire → · Earnings wire →

Dividends and capital return trailing yield 3.90%, quarterly · last 0.45 USD on 2026-08-14

Dividends and capital return

What GSK pays out and buys back — distributions read from the price series, money terms from the filings.

  • Trailing 12 months 1.82 USD per share · a 3.90% yield on the 2026-10-06 close 4 distributions, paid quarterly 2026-10-06
  • Change on the year +44.4% against the prior twelve months prior twelve months 1.26 USD per share
  • Last distribution 0.45 USD per share as the price series records it, within days of the ex-date 2026-08-14
  • By calendar year 2025: 1.67 USD (partial) · 2026: 1.40 USD to date first distribution recorded in the three-year window: 2025-02-21

Per-share amounts are derived from the adjusted price series in the listing currency, so dates sit within days of the ex-date; filing figures come from the fundamentals feed for the last reported fiscal year. An investment diary, not a recommendation.

FAQ · from the current data · as of 2026-10-07

Quick answers

What is GlaxoSmithKline PLC ADR (GSK)?

GlaxoSmithKline PLC ADR trades as GSK on the US exchange (US) in the Closelooknet research universe, as of the registry build of 2026-10-07.

Is GSK in a Closelooknet index?

Not currently — GlaxoSmithKline PLC ADR is tracked in the Closelooknet research universe but is not a constituent of a Closelooknet functional index as of 2026-10-07.

Where does GSK trade against its moving averages?

Mixed moving-average stack: Trades -7.3% vs the 50-day and -9.8% vs the 200-day average, 22.5% below the 52-week high and +12.6% off the 52-week low; a death cross printed 24 sessions ago. Computed from daily closes. As of 2026-10-06 — a technical state from the nightly Closelooknet bake, not advice. The Technical tab carries the full row.

How does GlaxoSmithKline PLC ADR compare with its peers?

Against its peer group (Drug Manufacturers - General · US), GlaxoSmithKline PLC ADR (GSK) sits 22.5% below its 52-week high, 7.3% below its 50-day average; Amgen Inc (AMGN) is 9.9% below, AbbVie Inc (ABBV) is 1.0% below, Gilead Sciences Inc (GILD) is 7.8% below. Put any of them next to GSK in the chart grid (2×1 or 2×2) and the page lays the companies side by side: performance, trend, valuation, margins and our money-flow reading.

How does GlaxoSmithKline PLC ADR trade when bond yields rise?

Over the past year GlaxoSmithKline PLC ADR had a beta of 0.72 to TLT, the long-dated Treasury fund — it moves strongly with bonds, higher than 72% of US names. On the 10 sessions in which long bonds fell most it moved −1.04% on average, against −0.74% for the S&P 500. The "How it trades on rate days" block on this page carries the lines.

What does GlaxoSmithKline PLC ADR do?

GSK researches, develops and manufactures vaccines and medicines through two segments, Commercial Operations and Total R&D. It sells specialty medicines for oncology, respiratory conditions and immune disease, vaccines against shingles, meningitis, RSV and other infections, and general medicines for asthma and COPD. It also runs partnerships, including work with CureVac on mRNA vaccines and AN2 Therapeutics on tuberculosis treatments. Closelooknet groups it with scored healthcare names sharing its sector and country: argenx, Medpace, BeiGene, Globus Medical, Regeneron, Veeva Systems, Vertex Pharmaceuticals and Corcept Therapeutics. The market also names Pfizer as a comparable large drugmaker.

Where does GlaxoSmithKline PLC ADR sit in the AI build-out?

GSK holds no seat in our index and sits outside the layers the diary tracks for the AI build-out. It belongs to the Healthcare sector of Closelooknet's universe, classified under drug manufacturers. GSK carries a Closelooknet score, with quality its strongest module and momentum its weakest. It has no index seat and no recorded quotes in the diary so far.

Does GlaxoSmithKline PLC ADR pay a dividend?

GlaxoSmithKline PLC ADR has paid 1.82 USD per share over the last twelve months, paid quarterly, a trailing yield of 3.90% on the 2026-10-06 close; the last distribution recorded in the price series was 0.45 USD on 2026-08-14. The "Dividends and capital return" block on this page carries the lines.

What has Wall Street done on GlaxoSmithKline PLC ADR recently?

The most recent analyst action on GlaxoSmithKline PLC ADR on the Closelooknet wire is a initiation by RBC Capital on 2026-09-08 (at Sector Perform). 1 action on the analyst wire since 2026-08-13: 1 initiation. Analyst actions are third-party opinions recorded by the wire, not Closelooknet readings. The “The Street on this name” block on this page lists the moves; the full feeds are the analyst wire and the earnings wire.

What does this page show?

A live price chart with SMA overlays and drawing tools for GSK, performance metrics, index-membership context and the Closelooknet structure read — an investment research diary view, not investment advice.

Related in the Closelooknet universe

then Drug Manufacturers - General, then Healthcare. Scored names rank on their Closelooknet score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.